Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Trial of Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease

NCT07708350 is registered in ClinicalTrials.gov with Daniel Bauer as lead sponsor.

NCT NCT07708350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07708350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Trial of Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease
Lead sponsor
Daniel Bauer
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 31, 2026
Completion date
December 31, 2030
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell anemia (hbss, or hbsβ-thalassemia0), sickle cell disease